Business
TherapeuticsMD and Afaxys Enter Into Agreement to Expand Access to ANNOVERA® in the U.S. Public Health Sector
BOCA RATON, Fla. & CHARLESTON, S.C.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, and Afaxys Pharma, LLC,
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":" BOCA RATON, Fla. & CHARLESTON, S.C.--(BUSINESS WIRE)--\nTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, and Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the public health system, announced today that they have entered into an agreement to expand access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system) in the United States public health sector. The arrangement combines Afaxys' unique experience and capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the United States public health system. TherapeuticsMD and Afaxys believe the arrangement will make ANNOVERA more widely accessible to patients in the United States. ANNOVERA is the first FDA-approved long-lasting reversible birth control that is patient-controlled and procedure free to provide a full year (13 cycles)* of protection against unintended pregnancy while fully under a woman’s control.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005098/en/\n\n\"We are pleased to be working with Afaxys, a recognized leader in serving women in the public health system,” said TherapeuticsMD Chief Executive Officer, Robert Finizio. “We have a strong and shared commitment to advancing women's health and increasing patient awareness of and access to ANNOVERA. We plan to leverage our arrangement with Afaxys to meet the needs of public health clinics, college and university health clinics, and city, county, state and federal facilities.”\n\n\n“The alliance with TherapeuticsMD allows Afaxys to expand its commitment to public health patients and the providers who care for them. We’re excited to work with TherapeuticsMD to broaden availability of ANNOVERA and provide a new treatment option for patients who want a long-lasting reversible contraceptive. We believe our expertise in contraceptive care and established relationships with public health providers will support a strong commercial presence for ANNOVERA in the market. This new alliance helps Afaxys deliver on its mission to bring innovative products to the public health family planning community and the patients they serve,” explained Ronda Dean, President and CEO of Afaxys, Inc.\n\n\n*For each cycle, ANNOVERA is inse...